Atlas Venture Life Science Advisors
Atlas Venture Life Science Advisors reported 9 stocks worth $631M in its 13F filing for Q3 2026, filed Nov 10, 2026. Its largest holdings are KYMR (50.4%), IRON (14.3%) and OBX (9.8%). Compared with Q2 2026, the fund opened new positions in OBX and ODTX and trimmed IRON, DYN and KRRO.
Latest filing: what Atlas Venture Life Science Advisors did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() KYMR Kymera Therapeutics Inc | $318M | 50.4% | 2.8M | No change | 8 of 8 | |
| 2 | ![]() IRON Disc Medicine Inc | $90.6M | 14.3% | 1.4M | −130K (−9%) | 8 of 8 | |
| 3 | ![]() OBX Obsidian Therapeutics Inc | $61.8M | 9.8% | 4.5M | New position | 1 of 8 | |
| 4 | ![]() KLRA Kailera Therapeutics Inc | $59.1M | 9.4% | 5.2M | No change | 2 of 8 | |
| 5 | ![]() DYN Dyne Therapeutics Inc | $55.4M | 8.8% | 3.4M | −3.4M (−49%) | 8 of 8 | |
| 6 | ![]() QTTB Q32 Bio Inc | $22.5M | 3.6% | 2.7M | No change | 8 of 8 | |
| 7 | ![]() SION Sionna Therapeutics Inc | $15.8M | 2.5% | 3M | No change | 7 of 8 | |
| 8 | ![]() KRRO Korro Bio Inc Com | $7.7M | 1.2% | 773K | −190K (−20%) | 8 of 8 | |
| 9 | ![]() ODTX Odyssey Therapeutics, Inc. | $60K | 0.0% | 2,692 | New position | 1 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 10, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Atlas Venture Life Science Advisors 13F FAQ
What does Atlas Venture Life Science Advisors own?
Atlas Venture Life Science Advisors reported 9 stocks worth $631M in its 13F filing for Q3 2026, filed Nov 10, 2026. Its largest holdings are KYMR (50.4%), IRON (14.3%) and OBX (9.8%). The table above lists every position in the filing (the top 10 without an account).
What did Atlas Venture Life Science Advisors buy and sell in Q3 2026?
Compared with Q2 2026: 2 new positions, 0 added to, 3 trimmed and 0 sold out. New positions include OBX and ODTX.
When will Atlas Venture Life Science Advisors file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Atlas Venture Life Science Advisors's portfolio worth?
The Q3 2026 filing reports $631M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.








